Key result
Myocardial infarction enhances cardiac AAV transduction in mice to improve gene therapy outcomes.
Why the study?
Approaches to enhance AAV-based cardiac gene transfer are key to successful cardiac gene therapy, but factors influencing AAV transduction remain poorly investigated.
Myocardial infarction creates a critical time window (peaking at day 3) that enhances AAV-based cardiac gene transfer, offering a strategy to boost cardiac gene therapy efficacy.
Approaches to enhance adeno-associated virus (AAV)-based cardiac gene transfer are the key to successful cardiac gene therapy, but factors influencing AAV transduction remain poorly investigated. This study showed that myocardial infarction (MI) enhanced cardiac AAV transduction, peaking at the third day post-MI in mice. The excessive AAV enrichment at the border zone is due to local vascular permeabilization and cardiomyocyte metabolic remodeling, which is independent of AAV dosage, serotypes and promoters. This effect was harnessed to boost cardiac base editing and improve the outcome of gene therapy for MI in mice. Thus, heart disease itself is a non-negligible factor that alters AAV-based cardiac gene transfer, which provides a new inroad to develop approaches to enhance cardiac gene therapy.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied Myocardial infarction. AAV-based cardiac gene transfer was evaluated on Cardiac AAV transduction. Myocardial infarction enhanced cardiac AAV transduction in mice, peaking at the third day post-MI, which was harnessed to improve the outcome of gene therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: